Key Takeaways
- Steady quarter, guidance held: Domestic formulations grew 14% YoY and export formulations grew 32% YoY, keeping the company on track for its 14–16% overall growth target.
- Zerodol umbrella brand hit ₹1,500 cr, becoming the 4th largest brand in IPM, with management confident in sustaining 14–15% growth for the next 3–4 years.
- Unichem margins were pinched by freight: EBITDA margin came in at ~11.3%, well below potential, because a spike in air shipments drove ~₹30 cr of extra freight expense.
- The balance sheet is now practically debt-free: Foreign-currency debt was fully repaid before the rupee depreciated, leaving ~₹700 cr in cash and only a small rupee term loan.
- What to watch next quarter: Whether Unichem’s freight costs normalize and margins recover, the sustainability of the institutional business surge, and any update on the Piska subsidiary’s path to profitability.
Domestic Formulations
- Chronic portfolio led the way: Chronic segment grew 20% versus the IPM’s 17%, while the acute segment grew 11%, roughly in line with the market. The acute performance was held back by declining antimalarials, marginal antibacterial growth, and low cough-and-cold growth.
- Pain management remains the engine: The Zerodol umbrella brand, covering rheumatoid arthritis and osteoarthritis, grew 16% in Q2 FY27. Volume growth contributed 8–9% and price growth added 4–4.5%.
- Top brands are consolidating their position: All six of Ipca’s top brands rank among the top 300 industry brands, with Zerodol SP holding the 11th rank.
Jain: "So on continuous basis, both our portfolio of rheumatoid arthritis and osteoarthritis, which includes Xerodol and all rheumatoid arthritis products, that has- they are continuously performing and continuously growing in the range of around 14 to 15% kind of range. So we have absolutely no concern on that. And in fact, from current Rs 1,500 crore of Umbrella brand, we are looking, uh, similar kind of growth to continue for next, uh, 3-4 years."
Export Formulations
- Broad-based generics surge: Standalone export formulations grew 32% YoY to ₹653 cr. Generics excluding tenders grew 36%, institutional generics grew 45%, and branded ROW grew 19%.
- Generics strength by geography: The US grew 31%, South Africa 46%, Canada 45%, ANZ 24%, and Europe 23% in Q2.
- UK subsidiary turned profitable: After a ~₹0.25 cr loss last fiscal year, the UK business returned to profit. The prior portfolio consisted of 15–20 year old genericized products sold below cost, but current market disruptions are pushing prices back up as short supplies emerge.
- Institutional business got a one-time lift: Strong H1 performance was partly driven by ~₹25 cr of shipments that shifted from the prior fiscal year into Q1 due to ship non-availability. This business is now expected to reach ₹325–340 cr in FY27, well above the earlier ₹300 cr guidance, but may decline next year.
- Branded business on track: H1 branded business grew ~22% overall, though one West Asia geography declined ~3% due to shipment timing issues. Management maintained the 15–16% growth guidance for the full year.
Jain: "But because of that kind of scenario, there are lots of disturbance in UK market today, uh, that a lot of products are going in short supplies and all, and prices are returning back because situation of selling product at lower price cannot continue for long."
Unichem Performance
- Freight costs crushed margins: Unichem’s EBITDA margin came in at ~11.3%, far below its potential. Other expenses rose ₹47 cr, of which ₹31.2 cr was freight, as the share of air shipments jumped from a normal 5–6% to ~25% because shipping-line delays forced the switch.
- Gross margin improved sequentially: Gross margin moved up to close to 58% QoQ, and management sees this as sustainable within a 1–2% band, subject to input cost variation.
- US portfolio showed mixed dynamics: Ipca’s own portfolio grew 74% in dollar terms, while the Unichem portfolio stood at $38.5M, with overall US dollar growth of ~9%.
- Margin recovery depends on freight normalization: If freight and energy costs ease, Unichem’s margins can move up; otherwise, they may remain in the 11–13% EBITDA range.
Margins & Balance Sheet
- Consolidated EBITDA margin improved: Margins rose to 22.97% from 21.68% YoY, despite significant increases in input, logistics, shipping, fuel, and energy costs. Standalone EBITDA margin improved to 26.61% from 25.46% YoY.
- Medium-term margin trajectory set: Management expects consolidated EBITDA to improve by ~1% to 1.25% per year, and standalone EBITDA by ~1.5% per year.
- Balance sheet strengthened materially: Foreign-currency debt was fully repaid before the rupee depreciation began. The company is now practically debt-free with ~₹700 cr in cash, and only a ~₹155 cr rupee term loan remains, which was not prepaid because its contracted rate is below current mutual-fund yields. That loan is expected to close the year at ~₹70–75 cr.
- Interest costs declining: Interest cost fell in Q2, and the run rate is expected to decline further in H2.
Jain: "Every year we should be improving by by almost around 1 percent to 1.25 percent of EBITDA on consolidated basis, and IPCA EBITDA will go by almost around 1.5 percent standalone EBITDA."
Subsidiaries
- All subsidiaries profitable except Piska: Piska has good API order positions but will take until the next financial year to start improving.
- UK returned to the black: The turnaround was driven by market disruption creating short supplies and pushing prices back up after a prolonged period of selling below cost.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Overall revenue growth | 14–16% (revised from 12–13%) | FY27 |
| Consolidated EBITDA margin | 22–23% | FY27 |
| Medium-term consolidated EBITDA improvement | ~1% to 1.25% per year | Medium-term, annual |
| Medium-term standalone EBITDA improvement | ~1.5% per year | Medium-term, annual |
| Zerodol umbrella brand growth | 14–15% range sustained | Next 3–4 years |
| Institutional business revenue | ₹325–340 cr (above earlier ₹300 cr guidance) | FY27 |
| Branded business growth | 15–16% | FY27 |
| Unichem EBITDA margin | 11–13% if freight/energy costs remain high | Ongoing |
| Rupee term loan | Close year at ~₹70–75 cr | FY27 |
| Piska subsidiary improvement | Profitability improvement | Next financial year |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹2,910 cr, +14% YoY from ₹2,557 cr |
| Consolidated EBITDA margin | 22.97%, improved from 21.68% in Q2 FY26 |
| Standalone EBITDA margin | 26.61%, improved from 25.46% in Q2 FY26 |
| Domestic formulation revenue | ₹1,157 cr, +14% YoY from ₹1,019 cr |
| Export formulation revenue (standalone) | ₹653 cr, +32% YoY from ₹493 cr |
| Promotional branded business revenue (ROW) | ₹172 cr, +19% YoY from ₹145 cr |
| Generic market revenue (ex-tender) | ₹364 cr, +36% YoY from ₹268 cr |
| Institutional generic business growth | ~45% YoY |
| API growth | ~6% YoY |
| Pain segment revenue | ₹628 cr, +16% YoY from ₹543 cr |
| Zerodol umbrella brand sales (IQVIA, September 2026) | ₹1,500 cr, 4th largest brand in IPM |
| IPCA market share (IQVIA, September 2026) | 2.11%, up from 2.09% in September 2026 |
| Unichem EBITDA margin | 11.3%, freight costs rose by ₹31.2 cr in other expenses |
| Unichem US portfolio sales | $38.5 million for the quarter |
| IPCA portfolio US sales (booked in Unichem) | $5.8 million for the quarter |
| Cash on books | ~₹700 cr |
| Rupee term loan borrowing | ~₹155 cr, expected to close year at ₹70–75 cr |